Guideline-directed medical therapy for heart failure in transthyretin amyloid cardiomyopathy
Cardiac amyloidosis is an underdiagnosed cause of infiltrative cardiomyopathy, leading to heart failure across the spectrum of ejection fractions. Although there are approved disease-modulating therapies for the transthyretin subtype (transthyretin amyloid cardiomyopathy [ATTR-CM]), the role of hear...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
18 February 2025
|
| In: |
Circulation. Heart failure
Year: 2025, Jahrgang: 18, Heft: 4, Pages: ? |
| ISSN: | 1941-3297 |
| DOI: | 10.1161/CIRCHEARTFAILURE.124.011796 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/CIRCHEARTFAILURE.124.011796 Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.124.011796 
|
| Verfasserangaben: | Stéphanie Kristina Schwarting, MD, Thomas Bieber, MD, MDRA, PhD, Daniel R. Davies, MD, Fabian aus dem Siepen, MD, Julian Schwarting, MD, Ulrich Grabmaier, MD, Steffen Massberg, MD, PhD, Mathew S. Maurer, MD, and Stefan Kääb, MD, PhD |
MARC
| LEADER | 00000naa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1938188160 | ||
| 003 | DE-627 | ||
| 005 | 20251010081643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251010s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCHEARTFAILURE.124.011796 |2 doi | |
| 035 | |a (DE-627)1938188160 | ||
| 035 | |a (DE-599)KXP1938188160 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schwarting, Stéphanie K. |e VerfasserIn |0 (DE-588)1338320661 |0 (DE-627)189820103X |4 aut | |
| 245 | 1 | 0 | |a Guideline-directed medical therapy for heart failure in transthyretin amyloid cardiomyopathy |c Stéphanie Kristina Schwarting, MD, Thomas Bieber, MD, MDRA, PhD, Daniel R. Davies, MD, Fabian aus dem Siepen, MD, Julian Schwarting, MD, Ulrich Grabmaier, MD, Steffen Massberg, MD, PhD, Mathew S. Maurer, MD, and Stefan Kääb, MD, PhD |
| 264 | 1 | |c 18 February 2025 | |
| 300 | |a ? | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.10.2025 | ||
| 520 | |a Cardiac amyloidosis is an underdiagnosed cause of infiltrative cardiomyopathy, leading to heart failure across the spectrum of ejection fractions. Although there are approved disease-modulating therapies for the transthyretin subtype (transthyretin amyloid cardiomyopathy [ATTR-CM]), the role of heart failure medications remains uncertain and challenging in clinical practice. Their effects on clinical outcomes, such as mortality and hospitalization, are unknown for ATTR-CM. This review aims to explore the use of these medications in ATTR-CM, considering the disease’s stage and patient-specific issues, such as fluid homeostasis, autonomic dysfunction, conduction disorders, low and fixed stroke volumes, and decreased functional capacity. As our understanding of this condition deepens, it is important to reassess the impact of contemporary heart failure medication in ATTR-CM. Finally, the relevance of guideline recommendations for heart failure drugs based on left ventricular ejection fraction should be reconsidered in the context of ATTR-CM. | ||
| 700 | 1 | |a Bieber, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Davies, Daniel R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Siepen, Fabian aus dem |d 1984- |e VerfasserIn |0 (DE-588)1066499969 |0 (DE-627)817646469 |0 (DE-576)426014944 |4 aut | |
| 700 | 1 | |a Schwarting, Julian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grabmaier, Ulrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Massberg, Steffen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Maurer, Mathew S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kääb, Stefan |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation. Heart failure |d Philadelphia, Pa. : Lippincott, Williams & Wilkins, 2008 |g 18(2025), 4, Artikel-ID e011796, Seite ? |h Online-Ressource |w (DE-627)567145719 |w (DE-600)2428100-1 |w (DE-576)299311058 |x 1941-3297 |7 nnas |a Guideline-directed medical therapy for heart failure in transthyretin amyloid cardiomyopathy |
| 773 | 1 | 8 | |g volume:18 |g year:2025 |g number:4 |g elocationid:e011796 |g pages:? |g extent:? |a Guideline-directed medical therapy for heart failure in transthyretin amyloid cardiomyopathy |
| 856 | 4 | 0 | |u https://doi.org/10.1161/CIRCHEARTFAILURE.124.011796 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.124.011796 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251010 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1066499969 |a Siepen, Fabian aus dem |m 1066499969:Siepen, Fabian aus dem |d 910000 |d 910100 |e 910000PS1066499969 |e 910100PS1066499969 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1338320661 |a Schwarting, Stéphanie K. |m 1338320661:Schwarting, Stéphanie K. |d 910000 |d 910100 |e 910000PS1338320661 |e 910100PS1338320661 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1938188160 |e 4784302026 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 10.10.2025"],"recId":"1938188160","type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Guideline-directed medical therapy for heart failure in transthyretin amyloid cardiomyopathy","title_sort":"Guideline-directed medical therapy for heart failure in transthyretin amyloid cardiomyopathy"}],"person":[{"given":"Stéphanie K.","role":"aut","roleDisplay":"VerfasserIn","display":"Schwarting, Stéphanie K.","family":"Schwarting"},{"family":"Bieber","role":"aut","roleDisplay":"VerfasserIn","given":"Thomas","display":"Bieber, Thomas"},{"family":"Davies","given":"Daniel R.","roleDisplay":"VerfasserIn","role":"aut","display":"Davies, Daniel R."},{"display":"Siepen, Fabian aus dem","roleDisplay":"VerfasserIn","role":"aut","given":"Fabian aus dem","family":"Siepen"},{"display":"Schwarting, Julian","role":"aut","roleDisplay":"VerfasserIn","given":"Julian","family":"Schwarting"},{"family":"Grabmaier","role":"aut","roleDisplay":"VerfasserIn","given":"Ulrich","display":"Grabmaier, Ulrich"},{"display":"Massberg, Steffen","given":"Steffen","role":"aut","roleDisplay":"VerfasserIn","family":"Massberg"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Mathew S.","display":"Maurer, Mathew S.","family":"Maurer"},{"family":"Kääb","roleDisplay":"VerfasserIn","role":"aut","given":"Stefan","display":"Kääb, Stefan"}],"language":["eng"],"physDesc":[{"extent":"? S."}],"name":{"displayForm":["Stéphanie Kristina Schwarting, MD, Thomas Bieber, MD, MDRA, PhD, Daniel R. Davies, MD, Fabian aus dem Siepen, MD, Julian Schwarting, MD, Ulrich Grabmaier, MD, Steffen Massberg, MD, PhD, Mathew S. Maurer, MD, and Stefan Kääb, MD, PhD"]},"id":{"eki":["1938188160"],"doi":["10.1161/CIRCHEARTFAILURE.124.011796"]},"origin":[{"dateIssuedDisp":"18 February 2025","dateIssuedKey":"2025"}],"relHost":[{"corporate":[{"display":"American Heart Association","roleDisplay":"Herausgebendes Organ","role":"isb"}],"id":{"issn":["1941-3297"],"eki":["567145719"],"zdb":["2428100-1"]},"titleAlt":[{"title":"Circulation / Heart failure"}],"recId":"567145719","part":{"text":"18(2025), 4, Artikel-ID e011796, Seite ?","extent":"?","year":"2025","pages":"?","volume":"18","issue":"4"},"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.2008 -"],"title":[{"title":"Circulation","title_sort":"Circulation","partname":"Heart failure","subtitle":"an official journal of the American Heart Association"}],"language":["eng"],"disp":"Guideline-directed medical therapy for heart failure in transthyretin amyloid cardiomyopathyCirculation. Heart failure","physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Philadelphia, Pa.","dateIssuedKey":"2008","publisher":"Lippincott, Williams & Wilkins","dateIssuedDisp":"2008-"}]}]} | ||
| SRT | |a SCHWARTINGGUIDELINED1820 | ||